重组多价疫苗
本发明涉及一种重组多价疫苗。其包括一种重组蛋白所述的重组蛋白从N端到C端包含第一抗原肽、N‑多肽(SEQ ID NO.1)、第二抗原肽、C‑多肽(SEQ ID NO.3)和第三抗原肽；其中，所述N‑多肽和C‑多肽是分子内骨架形成的多肽，用于支撑并稳定所述第一抗原肽、第二抗原肽和第三抗原肽的构象的分子内骨架NC。本发明提供了针对SARS‑CoV‑2变异株的重组多价疫苗3Ro‑NC(SEQ ID NO.17)和3Rs‑NC(SEQ ID NO.19)。本发明采用3Ro‑NC加KFD作为预防性黏膜SARS‑CoV‑2疫苗可以在上呼吸道和下呼吸道提供针对Omicron感染的保护。.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 23. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Chinesisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-23, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
CN117582492 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000353744 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000353744 | ||
| 003 | DE-627 | ||
| 005 | 20240322142810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||chi c | ||
| 035 | |a (DE-627)EPA000353744 | ||
| 035 | |a (EPA)CN117582492 | ||
| 035 | |a (EPA)89850762 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 245 | 1 | 0 | |a 重组多价疫苗 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-23, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 | ||
| 520 | |a 本发明涉及一种重组多价疫苗。其包括一种重组蛋白所述的重组蛋白从N端到C端包含第一抗原肽、N‑多肽(SEQ ID NO.1)、第二抗原肽、C‑多肽(SEQ ID NO.3)和第三抗原肽；其中，所述N‑多肽和C‑多肽是分子内骨架形成的多肽，用于支撑并稳定所述第一抗原肽、第二抗原肽和第三抗原肽的构象的分子内骨架NC。本发明提供了针对SARS‑CoV‑2变异株的重组多价疫苗3Ro‑NC(SEQ ID NO.17)和3Rs‑NC(SEQ ID NO.19)。本发明采用3Ro‑NC加KFD作为预防性黏膜SARS‑CoV‑2疫苗可以在上呼吸道和下呼吸道提供针对Omicron感染的保护。 | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 23. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89850762/publication/CN117582492A1?q=CN117582492 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 02 | ||